CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

$46.16 -1.10 (-2.33%)

(As of 11:30 AM ET)

CRISPR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 19 Analyst Ratings

Sell
2

Hold
8

Buy
9

Based on 19 Wall Street analysts who have issued ratings for CRISPR Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 8 have given a hold rating, and 9 have given a buy rating for CRSP.

Consensus Price Target

$74.94
62.34% Upside

According to the 19 analysts' twelve-month price targets for CRISPR Therapeutics, the average price target is $74.94. The highest price target for CRSP is $105.00, while the lowest price target for CRSP is $30.00. The average price target represents a forecasted upside of 62.34% from the current price of $46.16.

Get the Latest News and Ratings for CRSP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors.

CRSP Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	5 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$74.94	$75.19	$75.63	$69.88
Forecasted Upside	62.34% Upside	56.51% Upside	55.32% Upside	-0.86% Downside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

CRSP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CRISPR Therapeutics Stock vs. The Competition

Type	CRISPR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.37	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	58.56% Upside	26,931.27% Upside	9.84% Upside
News Sentiment Rating	Positive News See Recent CRSP News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/6/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Sector Perform ➝ Sector Perform	$53.00 ➝ $53.00	+5.98%
11/6/2024	Barclays 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$59.00 ➝ $55.00	+9.21%
11/6/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $84.00	+66.80%
8/12/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$120.00 ➝ $100.00	+110.84%
8/8/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral
8/6/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$112.00 ➝ $94.00	+89.29%
Get the Latest News and Ratings for CRSP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/6/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$60.00 ➝ $59.00	+18.81%
8/2/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+64.08%
6/28/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Chattopadhyay Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
6/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $105.00	+71.65%
5/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$89.00 ➝ $84.00	+50.27%
5/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$102.00 ➝ $95.00	+85.19%
5/9/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00	+61.65%
5/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $65.00	+24.12%
5/9/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$46.00 ➝ $52.00	-2.42%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$82.00 ➝ $99.00	+22.24%
2/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$46.00 ➝ $48.00	-43.64%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
12/11/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$30.00	-53.52%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$62.00 ➝ $63.00	+30.33%
5/30/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+15.99%
5/9/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$75.00	+38.63%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$44.00	-1.03%
3/17/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+54.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:41 AM ET.

CRSP Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for CRISPR Therapeutics is $74.94, with a high forecast of $105.00 and a low forecast of $30.00.
: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 2 sell ratings, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
: According to analysts, CRISPR Therapeutics's stock has a predicted upside of 62.34% based on their 12-month stock forecasts.
: CRISPR Therapeutics has been rated by research analysts at Barclays, Needham & Company LLC, and Royal Bank of Canada in the past 90 days.
: Analysts like CRISPR Therapeutics less than other "medical" companies. The consensus rating for CRISPR Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRSP compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

This page (NASDAQ:CRSP) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target